HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.
Mature enzymes encoded within the human immunodeficiency virus type 1 (HIV-1) genome (protease (PR), reverse transcriptase (RT) and integrase (IN)) derive from proteolytic processing of a large polyprotein (Gag-Pol). Gag-Pol processing is catalyzed by the viral PR, which is active as a homodimer. The HIV-1 RT functions as a heterodimer (p66/p51) composed of subunits of 560 and 440 amino acid residues, respectively. Both subunits have identical amino acid sequence, but p51 lacks 120 residues that are removed by the HIV-1 PR during viral maturation. While p66 is the catalytic subunit, p51 has a primarily structural role. Amino acid substitutions affecting the stability of p66/p51 (i.e. F130W) have a deleterious effect on viral fitness. Previously, we showed that the effects of F130W are mediated by p51 and can be compensated by mutation T58S. While studying the dynamics of emergence of the compensatory mutation, we observed that mutations in the viral PR-coding region were selected in HIV clones containing the RT substitution F130W, before the imposition of T58S/F130W mutations. The PR mutations identified (G94S and T96S) improved the replication capacity of the F130W mutant virus. By using a trans-complementation assay, we demonstrate that the loss of p66/p51 heterodimer stability caused by Trp130 can be attributed to an increased susceptibility of RT to viral PR degradation. Recombinant HIV-1 PRs bearing mutations G94S or T96S showed decreased dimer stability and reduced catalytic efficiency. These results were consistent with crystallographic data showing the location of both residues in the PR dimerization interface.
Olivares
Isabel
I
Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, E-28220, Madrid, Spain.
Mulky
Alok
A
Boross
Peter I
PI
Tözsér
József
J
Kappes
John C
JC
López-Galíndez
Cecilio
C
Menéndez-Arias
Luis
L
D000818:Animals; D002460:Cell Line; D019281:Dimerization; D004795:Enzyme Stability / Q000187:drug effects; D016333:HIV Protease / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism; D054303:HIV Reverse Transcriptase / Q000378:metabolism*; D015497:HIV-1 / Q000201:enzymology* / Q000235:genetics / Q000502:physiology; D006801:Humans; D009154:Mutation / Q000235:genetics*; D014508:Urea / Q000494:pharmacology; D014771:Virion / Q000201:enzymology* / Q000235:genetics / Q000502:physiology; D014779:Virus Replication / Q000235:genetics
D014508:Urea; D054303:HIV Reverse Transcriptase; D016333:HIV Protease